Twist Bioscience Q1 FY26: Record revenue $103.7M (+17% YoY), raises FY guidance to $435-440M

Twist Bioscience Corp

2026-Q1 EPS reported -$0.50 revenue$103,698,000

Revenue $103.7M (+17% YoY), 12th consecutive sequential growth; exceeded guidance.
Gross margin 52.0% (+4 pts YoY); net loss narrowed to $30.5M ($0.50/share) vs $31.6M.
DNA Synthesis & Protein Solutions rev $51.1M (+27% YoY); NGS Apps $52.6M (+8%, ex-large customer +18%).
FY2026 revenue guidance raised to $435-440M; reaffirms Q4 Adj EBITDA breakeven on track.
Cash $198M; shipped to ~2,538 customers, ~271,000 genes; launched research-grade plasmid DNA preps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.